A label-free dual immunosensor for the simultaneous electrochemical determination of CA125 and HE4 biomarkers for the early diagnosis of ovarian cancer

Kamaç, Melike Bilgi; Altun, Muhammed; Yılmaz, Merve; Sezgintürk, Mustafa Kemal

doi:10.1007/s00216-023-04569-y

Cited by 15 publications

(4 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison to other tools and methods proposed to date (including an ultrasensitive electrochemical immune sensor proposed for the assay of CA 72-4 by Yan et al [47]; an electrochemical sensor proposed for the simultaneous assay of CA19-9 and CA 72-4, which was based on tumor marker dual recognition via glycosyl imprinting and lectin-specific binding, proposed by Luo et al [48]; an ultrasensitive split-type electrochemical immunosensor based on the controlled-released strategy proposed by Li et al for the assay of CA 19-9 [49]; a photoelectrochemical immunosensor proposed by Gholamin et al for the assay of CA 19-9 [50]; a flower-shaped chemiluminescence-based sensor for the assay of CEA [51]; a magnetic copper silicate and boronic acid conjugate AuNCs@keratin-based electrochemical/fluorescent dual sensor proposed by Jin et al for the determination of CEA [52]; for the assay of CA 125, a hydrogel-based immunosensor proposed by Er et al [53]; and a label-free dual immunosensor proposed by Kamac et al [54]), the needle 3D stochastic microsensors proposed in this paper had the following advantages: The developed sensors exhibit reliable molecular recognition capabilities for CA 72-4, CA 19-9, CEA and CA 125, and they demonstrate wider working concentration ranges compared to those documented in the referenced papers. Additionally, the sensors achieve lower limits of determination and higher sensitivities, and their design, which does not involve the use of biomolecules, contributes to their enhanced stability over time.…”

Section: Response Characteristics Of the Two Stochastic Microsensors ...mentioning

confidence: 99%

Simultaneous Assay of CA 72-4, CA 19-9, CEA and CA 125 in Biological Samples Using Needle Three-Dimensional Stochastic Microsensors

Bratei,

Stefan-van Staden,

Ilie-Mihai

et al. 2023

Sensors

View full text Add to dashboard Cite

Two-needle 3D stochastic microsensors based on boron- and nitrogen-decorated gra-phenes, modified with N-(2-mercapto-1H-benzo[d]imidazole-5-yl), were designed and used for the molecular recognition and quantification of CA 72-4, CA 19-9, CEA and CA 125 biomarkers in biological samples such as whole blood, urine, saliva and tumoral tissue. The NBGr-2 sensor yielded lower limits of determination. For CEA, the LOD was 4.10 × 10−15 s−1 g−1 mL, while for CA72-4, the LOD was 4.00 × 10−11 s−1 U−1 mL. When the NBGr-1 sensor was employed, the best results were obtained for CA12-5 and CA19-9, with values of LODs of 8.37 × 10−14 s−1 U−1 mL and 2.09 × 10−13 s−1 U−1 mL, respectively. High sensitivities were obtained when both sensors were employed. Broad linear concentration ranges favored their determination from very low to higher concentrations in biological samples, ranging from 8.37 × 10−14 to 8.37 × 103 s−1 U−1 mL for CA12-5 when using the NBGr-1 sensor, and from 4.10 × 10−15 to 2.00 × 10−7 s−1 g−1 mL for CEA when using the NBGr-2 sensor. Student’s t-test showed that there was no significant difference between the results obtained utilizing the two microsensors for the screening tests, at a 99% confidence level, with the results obtained being lower than the tabulated values.

show abstract

Section: Response Characteristics Of the Two Stochastic Microsensors ...mentioning

confidence: 99%

Simultaneous Assay of CA 72-4, CA 19-9, CEA and CA 125 in Biological Samples Using Needle Three-Dimensional Stochastic Microsensors

Bratei,

Stefan-van Staden,

Ilie-Mihai

et al. 2023

Sensors

View full text Add to dashboard Cite

show abstract

“…However, the accuracy of detecting ovarian cancer using CA125 remains low [8,9]. Although combined detection methods have been developed, including the concurrent detection of proteins such as CA125 and Human epididymis protein 4 (HE4), their speci city and sensitivity are still di cult to meet the needs [10][11][12][13]. In recent years, continuous studies have shown that detection methods targeting miRNA and Circulating-tumor DNA (ctDNA) have greatly improved the accuracy of early cancer diagnosis [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Construction of scalable multi-channel DNA nanoplatform for the combined detection of multi-component biomarkers of cancer

Song,

Jin,

zhao

et al. 2024

Preprint

View full text Add to dashboard Cite

Single-level biomarker detection has the limitation of insufficient accuracy in cancer diagnosis. Therefore, the strategy of developing highly sensitive, multi-channel biosensors for multi-component biomarkers analysis is critical to improve the accuracy of early diagnosis of clinical tumors. Herein, in order to achieve efficient detection of up to ten targets for early diagnosis of ovarian cancer, a DNA-nanoswitch-based multi-channel (DNA-NSMC) biosensor was built based on the multi-module catalytic hairpin assembly-mediated signal amplification (CHA) and toehold-mediated DNA strand displacement (TDSD) reaction. In this work, only two different fluorescence signals are used as outputs, combined with modular segmentation strategy of DNA-nanoswitch-based reaction platform, the multi-channel detection of up to 10 targets is successfully achieved for the first time. The experimental results suggest that the proposed biosensor is a promising tool for simultaneously detecting multiple biomarkers for the early diagnosis of ovarian cancer, offering new strategies for the early screening, diagnosis, and treatment not only for ovarian cancer but also for other cancers.

show abstract

“…Human epididymis protein 4 (HE4) levels have certain utility in the early diagnosis, differential diagnosis, and therapeutic monitoring of ovarian cancer. 8 , 9 CA125, a tumor-associated antigen on the surface of ovarian tumor cells, is important in the diagnosis of ovarian cancer. 10 CA199 is a tumor marker with potential value in the diagnosis of ovarian tumors because of its abnormal expression in ovarian tumors.…”

Section: Introductionmentioning

confidence: 99%

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer

Tan,

Zou,

Chen

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

Objective To compare the efficacy of paclitaxel liposomes combined with carboplatin and paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer and assess their effects on serum human epididymis protein 4 (HE4), CA125, CA199, matrix metalloproteinase-2 (MMP2), MMP-7, and MMP-9 levels. Methods In this observational study, 102 patients with advanced ovarian cancer were assigned to receive paclitaxel liposomes combined with carboplatin (Group A) or paclitaxel combined with carboplatin (Group B). Clinical efficacy; serum HE4, CA125, CA199, MMP-2, MMP-7, and MMP-9 levels; and the occurrence of adverse reactions were compared between the groups. Results The overall response rate was significantly higher in Group A than in Group B. After chemotherapy, serum HE4, CA125, CA199, MMP-2, MMP-7, and MMP-9 levels were lower in Group A than in Group B. The incidence of myalgia, dyspnea, nausea and vomiting, facial flushing, peripheral neuropathy, and skin rash was lower in Group A than in Group B. Conclusion Paclitaxel liposomes combined with carboplatin displayed better efficacy in the treatment of advanced ovarian cancer than paclitaxel combined with carboplatin, which might be attributable to reductions in serum marker levels and the occurrence of adverse events.

show abstract

A label-free dual immunosensor for the simultaneous electrochemical determination of CA125 and HE4 biomarkers for the early diagnosis of ovarian cancer

Cited by 15 publications

References 58 publications

Simultaneous Assay of CA 72-4, CA 19-9, CEA and CA 125 in Biological Samples Using Needle Three-Dimensional Stochastic Microsensors

Simultaneous Assay of CA 72-4, CA 19-9, CEA and CA 125 in Biological Samples Using Needle Three-Dimensional Stochastic Microsensors

Construction of scalable multi-channel DNA nanoplatform for the combined detection of multi-component biomarkers of cancer

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer

Contact Info

Product

Resources

About